NanoBone was tested alone in the American Society for Testing and Materials International standardized animal model and found to be equivalent to the “gold standard” autograft in fusion rate.
NanoBone Bone Graft products have been used in Europe and the U.S. for over 10 years in more than 100,000 clinical cases across all indications and have been made available in the U.S. via Artoss since 2015.
More articles on devices:
Robotic surgical assistant aims to improve knee replacement outcomes: 5 insights
Zimmer Biomet Q1 net sales hit $1.97B amid declines in the Americas: 5 things to know
Orthopedics drives Conmed’s quarterly growth — 5 insights
